中国生物制药(01177.HK) 公布,以自筹资金入股礼新医药,并就LM-108及未来潜在的多个创新双特异性抗体或抗体偶联药物(ADC)在中国地区达成战略合作。礼新医药于10月18日宣布完成3亿元人民币C1轮融资,募集资金用于加快推进临床管线药物开发和创新平台建设。根据增资认购协议,集团作为本轮融资领投方,向礼新医药支付1.42亿元人民币,取得本次交易后礼新医药4.91%的股权。LM-108是礼新...
Source Link中国生物制药(01177.HK) 公布,以自筹资金入股礼新医药,并就LM-108及未来潜在的多个创新双特异性抗体或抗体偶联药物(ADC)在中国地区达成战略合作。礼新医药于10月18日宣布完成3亿元人民币C1轮融资,募集资金用于加快推进临床管线药物开发和创新平台建设。根据增资认购协议,集团作为本轮融资领投方,向礼新医药支付1.42亿元人民币,取得本次交易后礼新医药4.91%的股权。LM-108是礼新...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.